Kala Pharmaceuticals announced that it will host a key opinion leader symposium on the unmet need in dry eye disease and the potential for Eysuvis as a short-term treatment for the signs and symptoms of the disease. The event will be held virtually on Thursday, September 17, 2020, beginning at 8 am ET.
Scheduled to speak at the event are Edward J. Holland, MD, Director of Cornea Services at Cincinnati Eye Institute and Professor of Ophthalmology at the University of Cincinnati, and Kelly K. Nichols, OD, MPH, PhD, FAAO, Dean of the School of Optometry at the University of Alabama at Birmingham.
Additionally, Kala management will present an update on launch planning for Eysuvis. A new drug applicaton (NDA) for Eysuvis is currently under review by the FDA with a Prescription Drug User Fee Act (PDUFA) goal date of October 30, 2020. If approved, Kala expects to launch Eysuvis before year-end.
To access the event, please dial 866-300-4091 (domestic callers) or 703-736-7433 (international callers) 5 minutes prior to the start of the event and provide the conference ID 7985989. Additionally, a live webcast and subsequent archived recording of the presentation will be available under “Events” in the “Investors” section of the Kala website at http://kalarx.com